Ami Organics Ltd
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]
- Market Cap ₹ 4,487 Cr.
- Current Price ₹ 1,231
- High / Low ₹ 1,389 / 845
- Stock P/E 52.6
- Book Value ₹ 163
- Dividend Yield 0.24 %
- ROCE 20.6 %
- ROE 15.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 35.3% CAGR over last 5 years
Cons
- Stock is trading at 7.64 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|
160 | 188 | 239 | 240 | 341 | 520 | 617 | 628 | |
137 | 157 | 196 | 198 | 260 | 415 | 493 | 503 | |
Operating Profit | 23 | 31 | 42 | 42 | 80 | 105 | 123 | 125 |
OPM % | 14% | 16% | 18% | 17% | 24% | 20% | 20% | 20% |
0 | 3 | 0 | 2 | 1 | 3 | 4 | 5 | |
Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 3 |
Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 13 |
Profit before tax | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 114 |
Tax % | 35% | 35% | 34% | 21% | 25% | 21% | 26% | |
12 | 18 | 23 | 27 | 54 | 72 | 83 | 85 | |
EPS in Rs | 80.33 | 123.33 | 22.19 | 26.16 | 17.14 | 19.75 | 22.86 | 23.37 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 37% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 35% |
3 Years: | 44% |
TTM: | 17% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 38% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 20% |
Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
2 | 2 | 10 | 10 | 32 | 36 | 36 | |
Reserves | 37 | 56 | 72 | 101 | 135 | 486 | 558 |
27 | 44 | 54 | 59 | 137 | 1 | 4 | |
43 | 54 | 77 | 61 | 110 | 136 | 169 | |
Total Liabilities | 109 | 155 | 213 | 232 | 413 | 659 | 767 |
28 | 32 | 79 | 85 | 186 | 205 | 259 | |
CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 |
Investments | 1 | 3 | 2 | 2 | 1 | 2 | 2 |
68 | 91 | 131 | 133 | 225 | 450 | 477 | |
Total Assets | 109 | 155 | 213 | 232 | 413 | 659 | 767 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
29 | 8 | 15 | 27 | 28 | -12 | 66 | |
-19 | -25 | -21 | -24 | -101 | -121 | -33 | |
-7 | 15 | 6 | 0 | 72 | 140 | -12 | |
Net Cash Flow | 3 | -2 | -0 | 3 | -1 | 8 | 20 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|
Debtor Days | 83 | 97 | 116 | 86 | 129 | 115 | 136 |
Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 |
Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 157 |
Cash Conversion Cycle | 11 | 31 | 43 | 88 | 80 | 107 | 111 |
Working Capital Days | 46 | 64 | 68 | 86 | 119 | 141 | 149 |
ROCE % | 38% | 34% | 27% | 33% | 24% | 21% |
Documents
Announcements
- Closure of Trading Window 19h
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
1d - Reappointment of M/s Maheshwari & Co. as the Statutory Auditors of Company for a second term of five consecutive years.
- Corrigendum To Voting Results And Scrutinizers Report Dated September 26, 2023. 1d
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 2d
- Announcement under Regulation 30 (LODR)-Allotment 25 Sep
Annual reports
Concalls
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
Leading specialty chemical Company
With a legacy of 14 years, the Company has developed and commercialized over 450 pharma intermediates across 17 key therapeutic areas since inception and NCE, which are being supplied to over 450 customers in India and 50 countries overseas. [1] [2]